Cell Bridge Strategies

What Cell Bridge Strategies does

Cell Bridge Strategies, LLC is a privately held, US-based boutique consulting firm headquartered in Boerne, Texas, with a globally distributed practitioner network. The firm provides strategic advisory services to life sciences companies—spanning biotechnology, pharmaceutical, medical device, and investor clients—focused on regenerative medicine, cell therapy, cell & gene therapy, and biomanufacturing. Its stated mission is to bridge scientific research and commercial outcomes through engagements that span R&D strategy, clinical and regulatory navigation, biomanufacturing scale-up, market and competitive intelligence, and M&A or funding support.

The firm's service catalog is organized around six core offerings: Situational Analysis & Planning, Roadmaps, Business Strategies, Scientific Strategy & Development, Cell Gene Therapy & Biomanufacturing Ecosystem, and Translational Analysis. Delivery is anchored in proprietary methodologies including Top-Down & Bottom-Up Analysis, Translational Analysis, and the Production, Capacity, and Consumption (PCC) Model—a custom competitive intelligence database and modeling system used to triangulate production, capacity, and consumption data across multiple geographies and competitors. The team is led by Founder & CEO Dr. Jane C. Andrews, Ph.D., and includes principal consultants with prior executive roles at Frost & Sullivan, BioBridge Global, Pfizer, Terumo BCT, Scorpion Biological Services, and NASA-adjacent work via Lockheed Martin.

The business model is professional services consulting with a sales-led go-to-market motion. Cell Bridge Strategies offers a free 30-90 minute initial consultation as its primary lead capture mechanism, after which engagements are scoped and staffed by drawing from a core consultant base and a global partner network of subject-matter experts and key opinion leaders. Revenue is generated through project-based consulting engagements; pricing and contract values are not publicly disclosed. The firm maintains reciprocal partnerships with Cell One Partners, Court Square Group, and LeanRAQA, and supports demand generation through blog content, email newsletters, and conference speaking by leadership.

Name

Cell Bridge Strategies

Legal name

Cell Bridge Strategies, LLC

Website

https://cellbridgestrategies.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Cell Bridge Strategies is a US-based boutique consulting firm serving biotech, pharma, and medical device clients with strategic advisory services in regenerative medicine, cell therapy, and biomanufacturing, using proprietary analytical methodologies to bridge science and commercial outcomes.

Ownership category

akta.pro rank

Product category

Life Sciences Consulting

NAICS

Management Consulting Services (54161), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Process Development & Tech Transfer Services (CDMO) (HLAGABAL)

Keywords

• Life sciences consulting
• Regenerative medicine consulting
• Cell therapy strategy
• Biomanufacturing consulting
• Market intelligence services

Headquarters

HQ city

Boerne

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Strategic Consulting Services: Professional consulting services spanning R&D, clinical, regulatory, financial, and commercial strategies. Services include strategy development, market navigation, situational analysis, translational development, and biomanufacturing ecosystem guidance. Revenue is generated through consulting engagements with life sciences companies, biotech startups, research organizations, and pharmaceutical/medical device companies.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Cell Bridge Strategies is a global life sciences consulting firm that advises biotechnology, pharmaceutical, and regenerative medicine companies on transforming breakthrough science into market-ready products. The firm delivers strategy, market intelligence, biomanufacturing, regulatory, and commercialization advisory services across regenerative medicine, cell therapy, cell & gene therapy, and biomanufacturing domains, using proprietary Top-Down & Bottom-Up analytical models and Translational Analysis methodology.

Product overview

Cell Bridge Strategies is a life science consulting firm offering a comprehensive suite of advisory services rather than a software product platform. The firm provides consulting engagements across six core service areas: Situational Analysis & Planning, Roadmaps, Business Strategies (including proprietary Top-Down/Bottom-Up™ Analysis), Scientific Strategy & Development, Cell Gene Therapy & Biomanufacturing Ecosystem, and Translational Analysis. These services are delivered through strategic consulting engagements and supported by proprietary methodologies for market analysis and financial modeling. The firm also offers specialized consulting in Regenerative Medicine and Cell & Gene Therapy. Case study examples demonstrate work in competitive intelligence, market opportunity identification, investor strategy, and geographic market expansion.

Differentiator

Problem solved

Functional benefit

Products and services

• Situational Analysis & Planning Comprehensive assessment of a company's current business model, capabilities, strategy, assets, and market positioning, including internal SWOT assessment and needs assessment to identify challenges and opportunities. Intended for life sciences executives seeking a clear path forward.
• Roadmaps Defining strategic milestones for product development, R&D, biomanufacturing (including cGMP) build-out, geographic expansion, and process mapping to accelerate client success. Intended for life sciences companies scaling operations.
• Business Strategies Strategic consulting including Top-Down / Bottom-Up analysis, market and competitive intelligence, partnership and M&A target identification, financial planning, growth roadmaps, and business development support. Intended for life sciences executives seeking to grow, scale, and navigate industry challenges.
• Scientific Strategy & Development Alignment of scientific innovation with business goals covering pre-clinical and clinical development, process development, indication-specific R&D, new product development, and Top-Down / Bottom-Up analysis. Intended for biotech and pharma R&D leaders.
• Cell Gene Therapy & Biomanufacturing Ecosystem Optimization of manufacturing processes and market positioning for cell and gene therapy, supporting pharma, biotech, device, and CRO partners with national and international market expertise. Intended for cell and gene therapy developers and manufacturers.
• Translational Analysis Methodology that aligns research goals with business objectives to enable seamless transition from laboratory innovation to commercialized products. Intended for life sciences R&D and commercial leadership teams.
• Regenerative Medicine Consulting Strategic guidance for developing and commercializing cutting-edge therapies including stem cell therapies, tissue engineering, and cellular medicine with regulatory navigation and clinical trial support. Intended for regenerative medicine companies and investors.
• Cell & Gene Therapy Consulting Full lifecycle support for cell and gene therapy development from pre-clinical research through clinical trials and commercialization, including manufacturing optimization and regulatory navigation. Intended for biotech companies and research organizations developing cell and gene-based therapies.

Quantifiable outcome

• Market expansion and increased profit margins through new 3-part business model for regenerative medicine client in Japan
• +2 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor and core.

• LeanRAQAminorImplementation/ SI/ Consulting PartnerLeanRAQA provides regulatory affairs and quality assurance consulting to life sciences and medical device industries. They help organizations streamline compliance and accelerate time-to-market using lean methodologies, ensuring regulatory readiness at every stage of development.
• Cell One PartnerscoreStrategic or Co-development PartnerCell One Partners supports cell and gene therapy companies from early development through commercialization, offering expertise in clinical strategy, regulatory pathways, manufacturing, and talent planning. Dr. Jane Andrews serves as a core team member of Cell One Partners, and Cell Bridge Strategies collaborates on helping companies bring advanced therapies to market.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• L.E.K. Consulting: Global management consulting firm with a deep life sciences practice serving biotech, pharma, and medtech on commercial strategy, M&A, and market entry. Represents a larger-scale competitor with overlapping capabilities in life sciences strategy consulting.
• Frost & Sullivan: Global growth consulting and market intelligence firm with a dedicated life sciences practice. Multiple Cell Bridge team members (Dr. Jane Andrews, Nadav Ofir, Hilal Cura) are former Frost & Sullivan consultants, making it the most direct professional lineage and a benchmark competitor in life sciences strategy consulting.
• Charles River Associates: Global consulting firm with a substantial Life Sciences practice offering strategy, economics, and regulatory expertise to pharmaceutical and biotech clients. A larger-scale, broader incumbent operating in overlapping service categories with Cell Bridge.

Direct peers

• Health Advances: Boutique healthcare and life sciences strategy consulting firm focused on commercial strategy, due diligence, and product development for biopharma, medtech, and diagnostics clients. Comparable to Cell Bridge in serving similar buyer profiles and offering analogous strategy and market navigation services.
• Trinity Partners: Specialist life sciences consulting firm focused on biopharma commercial strategy, including market assessment, competitive intelligence, and forecasting. Comparable to Cell Bridge in service mix and customer profile, with similar boutique positioning in life sciences.
• Back Bay Life Science Advisors: Boutique life sciences strategy consulting firm advising therapeutics, medical devices, and diagnostics companies on commercialization, financing, and licensing. Comparable in scale and specialization to Cell Bridge, with a similar focus on early- and growth-stage life sciences clients.
• Alacrita Consulting: Boutique life sciences consulting firm providing strategic and operational support to pharma, biotech, and medtech clients, with particular depth in cell and gene therapy and biomanufacturing. Closely mirrors Cell Bridge's therapeutic focus and boutique positioning.
• ClearView Healthcare Partners: Life sciences consulting firm providing strategic and commercial insights to biopharmaceutical, medical device, and diagnostics clients across the product lifecycle. Closely overlaps Cell Bridge's service portfolio (strategy development, market navigation, competitive intelligence) and customer base.
• Cell One Partners: Specialist consultancy supporting cell and gene therapy companies from early development through commercialization. Cell Bridge's core strategic partner, with Dr. Jane Andrews serving as a core team member — making it both a peer and an embedded partner in the same niche.
• J.R. Stockton Consulting, LLC: Process engineering and biomanufacturing consultancy run by Cell Bridge Principal Consultant Rick Stockton. Directly comparable in scale, niche focus on biomanufacturing/facility planning, and operating model (solo principal with global reach).

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/cell-bridge-strategies

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cell Bridge Strategies